Visitar a amigos, ir al cine o hacer trabajos voluntarios activan regiones específicas del cerebro necesarias para el reconocimiento de caras y emociones, la toma de decisiones y sentirse recompensad...
Read moreSparingVision (“the Company”), a genomic medicine company focused on ocular diseases, today announces a €44.5 million financing round. The round was led by 4BIO Capital (“4BIO”) and UPMC Ent...
Read moreHighlight Therapeutics, (“Highlight”), a clinical-stage biopharmaceutical company developing RNA-based therapies against cancer, and Pivotal, a Europe-wide full-service CRO, today announced tha...
Read moreEl consejero de Sanidad, Enrique Ruiz Escudero, ha asistido hoy a la presentación de los resultados preliminares del ensayo clínico, en el que han participado 13 hospitales españoles de los que 7 s...
Read moreThe Catalan biopharmaceutical company AbilityPharma, focused on the development of innovative oral anticancer compounds, undertakes the last stage of the investment round with which this year it will ...
Read moreEste compuesto muestra un perfil de seguridad y tolerabilidad satisfactorio como monoterapia en pacientes diagnosticados con leucemia mieloide aguda refractaria.
Read moreSe trata de dispositivos inteligentes y portátiles acoplados al calzado para registrar parámetros como el modo de caminar, las irregularidades de la marcha y la actividad física
Read moreOryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, today reported ...
Read moreThe Biochemical Research Group of Oxidative Stress leads the project
Read morePilar Barretina, del ICO Girona, y Marta Gil, del ICO L'Hospitalet, han participado en el estudio Garnet, publicado en la revista científica 'JAMA Oncology', Los resultados muestran que el fármaco a...
Read moreDr. Kulisevsky, director of the Movement Disorders Unit of the Sant Pau Hospital Neurology Service and head of the Parkinson’s Disease and Movement Disorders Research Group at the Sant Pau Research ...
Read moreMinoryx Therapeutics, a Phase 3 clinical stage biotech company focused on the development of differentiating treatment options in orphan central nervous system (CNS) disorders, today announces that th...
Read more